Structural insight into the macrocyclic inhibitor TPX-0022 of c-Met and c-Src

c-Met has been an attractive target of prognostic and therapeutic studies in various cancers. TPX-0022 is a macrocyclic inhibitor of c-Met, c-Src and CSF1R kinases and is currently in phase I/II clinical trials in patients with advanced solid tumors harboring MET gene alterations. In this study, we...

Полное описание

Библиографические подробности

Главные авторы:	Lingzhi Qu, Hang Lin, Shuyan Dai, Ming Guo, Xiaojuan Chen, Longying Jiang, Huajun Zhang, Maoyu Li, Xunjun Liang, Zhuchu Chen, Hudie Wei, Yongheng Chen
Формат:	Artigo
Язык:	Inglês
Опубликовано:	American Association for the Advancement of Science (AAAS) 2023-01-01
Серии:	Computational and Structural Biotechnology Journal
Предметы:	C-Met TPX-0022 Crystal structure Resistance-relevant mutations C-Src
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2001037023004439
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!